Status:
RECRUITING
Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure
Lead Sponsor:
Careggi Hospital
Collaborating Sponsors:
University of Florence
Conditions:
Critical Illness
Acute Kidney Injury
Eligibility:
All Genders
Brief Summary
The use of extracorporeal blood purification therapies (EBPT) is becoming increasingly widespread worldwide in everyday clinical practice, particularly in the critical care setting. Nonetheless, most ...
Detailed Description
The use of extracorporeal blood purification therapies (EBPT) is becoming increasingly widespread worldwide in everyday clinical practice, particularly in the critical care setting. For most of these ...
Eligibility Criteria
Inclusion
- critically ill patients in the ICU
- one of this EPB therapy:
- CRRT/IHD/Hybrid therapies for support//replacement renal function
- immunomodulation achieved by "high cut-off membranes", "endotoxins and/or cytokines adsorbent membranes" or by high-volume hemofiltration
Exclusion
- patients treated only by Cytosorb® and/or Toraymyxin® therapies
Key Trial Info
Start Date :
July 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04033224
Start Date
July 16 2019
End Date
September 30 2025
Last Update
February 12 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale S. Giuseppe
Empoli, Firenze, Italy, 50053
2
Ospedale Versilia
Lido di Camaiore, Lucca, Italy, 55049
3
Humanitas Research Hospital
Rozzano, Milano, Italy, 20089
4
IRCCS Policlinico S. Donato
San Donato Milanese, Milano, Italy, 20097